ABSTRACT
Lymphoid follicles (LFs) can be induced in the lung on infection or chronic inflammation; however, their relevance and contribution to protective immunity or pathogenesis is poorly understood. Recent advances from clinical studies and animal models have shed some light on the mechanisms that trigger and facilitate the development of LFs. As we grasp a better understanding of their development and their relevance to disease, the potential value in targeting pulmonary LFs with novel therapeutics will become evident.

INTRODUCTION
The adaptive immune response is initiated in secondary lymphoid organs (SLOs) such as lymph nodes and the spleen. These organs are specialised to enhance interactions between circulating lymphocytes and antigen presenting cells. On encountering antigens specific to their cognate receptors, T and B lymphocytes clonally expand within SLOs and are then recruited to the site of inflammation where they exert their effector function. Given the potentially deleterious impact of T and B cell function, the formation of SLOs is tightly controlled and occurs during embryogenesis at specific developmental windows and predefined anatomical locations.

However, after birth, de novo formation of ectopic lymphoid follicles (LFs) can occur at mucosal surfaces such as the lung and intestine. Their formation in the lung is associated with infection or inflammation. Accordingly, one could propose that they have emerged to enhance immune responses locally and compliment the functionality of SLOs. However, one could also expect that enhanced local immune responses deriving from LFs could contribute to immune pathology associated with chronic inflammation. LFs within the lung exhibit varying degrees of structural organisation and can be located in association with a bronchiolae, pulmonary vessel or in the interstitium. The most organised of these ectopic LFs are referred to as tertiary lymphoid organs and exhibit a structural similarity to SLOs, such as distinct B and T cell areas, germinal centres, high endothelial venules and follicular dendritic cell networks.

FACTORS INVOLVED IN THE DEVELOPMENT OF LFS
There is a certain overlap between the pathways involved in the development of SLOs and inducible LFs. The development of SLOs is dependent on specialised cells called lymphoid tissue inducer (LTI) cells that drive lymphotoxin dependent expression of the homeostatic chemokines CCL19, CCL21 and CXCL13. Although these homeostatic chemokines are also important for the formation of LFs, the necessity for LTI cells in the development of LFs is controversial. Indeed, a recent study by Rangel-Moreno et al showed that in neonatal mice, endotoxin induced ectopic pulmonary lymphoid tissue can form in the absence of LTI cells. Instead, T cells producing the cytokine interleukin 17 were sufficient for their formation through induction of lymphotoxin independent expression of CXCL13. Given the association of Th17 cells with chronic inflammation and autoimmunity, the formation of LFs in these conditions could in principle also be a component of interleukin 17 mediated pathology (figure 1).

RELEVANCE OF LFS TO DISEASE
The formation of pulmonary lymphoid aggregates can be triggered by a variety of stimuli, such as microbial infections and inflammation. Consequently, pulmonary LFs are rarely found in healthy adults whereas they are enriched in chronic disease such as chronic obstructive pulmonary disease (COPD). The landmark paper by Hogg et al provided a compelling association between the progression of COPD and the frequency of airways containing LFs, although their role in the disease itself remains elusive. One can speculate that these LFs develop to limit or counteract infection of the airways, which can follow breach of the epithelial barrier in diseased lungs. On the other hand, the breakdown products of the lung tissue that accumulate in the lungs could also be presented within the LFs, giving rise to B and T cell responses directed against self-antigens and thus perpetuate the ongoing disease.

There are conflicting reports regarding the presence of autoantibodies in COPD patients. One of the major caveats in such studies is the definition of an appropriate self-antigen as this may vary, even between subjects exhibiting similar disease severity in terms of clinical symptoms. Moreover, many of these studies measure levels of circulating autoantibodies in the serum of patients. As COPD is seldom linked to systemic autoimmunity, the production of autoantibodies might be localised within the LFs and thus evaluation of their levels within the airways would be more relevant. Van der Strate et al have demonstrated that B cells within pulmonary LFs of COPD patients exhibit an antigen specific oligoclonal activation. Building on the potential for B cell mediated pathology in COPD, Feghali-Bostwick et al showed the presence of immune complexes and complement within diseased lungs. In addition, they found increased levels of autoantibodies directed against the...
pulmonary epithelium that also displayed pathogenic potential, as measured by their ability to mediate antibody dependent cell mediated cytotoxicity. Although these studies allude to a role for LFs in driving immunopathology in COPD, conclusive mechanistic evidence is still lacking.

In addition to chronic inflammation, infections are also known to trigger the formation of LFs. In these situations, LFs could serve as a site for induction of specific immune responses. In fact, such localised responses in addition to being protective might also be less pathogenic in comparison with systemic immune responses. Wiley et al. studied the role of LFs in the context of protective immunity. They found that induction of LFs by instillation of protein nano cage particles enhances immune responses to primary viral infections while curtailing the extent of bystander damage to the lungs. Of note, this effect mediated by the LFs was not specific and resulted in protection against different viral infections.

CONCLUSION
It is important to bear in mind that LFs could play a role in protective immunity as well as in immunopathologies. In chronic lung diseases such as COPD, LFs might develop as an intrinsic means of protecting a damaged tissue by enhancing local immune responses; in such cases, therapeutics targeting them could further predispose individuals to infection induced exacerbations. Alternatively, LFs could be key to the pathology and chronicity of COPD, and targeting them could reduce the progression and severity of the disease. Clearly, it is important that we discover the functional role of pulmonary LFs such that rational approaches can be developed to ameliorate the inflammatory environment characteristic of chronic lung diseases.

Contributors This manuscript was written by KY and BJM.

Funding BJM is a Cloetta Medical Research Fellow. This work has been supported by the Swiss National Science Foundation (grant No. 310030.130029).

Competing interests None.

Provenance and peer review Commissioned; not externally peer reviewed.

REFERENCES
Lymphoid follicles in chronic lung diseases

Koshika Yadava and Benjamin J Marsland

Thorax 2013 68: 597-598 originally published online January 8, 2013
doi: 10.1136/thoraxjnl-2012-203008

Updated information and services can be found at:
http://thorax.bmj.com/content/68/6/597

These include:

References
This article cites 5 articles, 0 of which you can access for free at:
http://thorax.bmj.com/content/68/6/597#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Inflammation (1020)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/